Epigral has received approval for raising of funds through issuance of instruments or security including equity shares or any other eligible securities by way of one or more public and/or private offerings including on a preferential allotment basis and/or a qualified institutions placement for an amount not exceeding Rs 500 crore in terms of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the SEBI ICDR Regulations) and/or any other permissible mode(s), in accordance with the SEBI ICDR Regulations and other applicable regulations, subject to necessary approvals including the approval of the members of the Company and such other regulatory/ statutory approvals as may be required. The Board of Directors of the company in its meeting held on August 14, 2024 has approved the same.
Epigral, formerly known as Meghmani Finechem, is a leading integrated manufacturer of chemicals in India.
